Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis

Iranian Journal of Kidney Diseases

Volumn 3, Issue 3, 2009, Pages 151-155

  Shahbazian, Heshmatollah ^a   Moghadam, Ahmad Zand ^a   Ehsanpour, Ali ^a   Khazaali, Mahyar ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; Hypoxanthine; Purine nucleotides; Uremia; Uric acid

Indexed keywords

HYPOXANTHINE; URIC ACID; BICARBONATE; BIOLOGICAL MARKER; HEMODIALYSIS FLUID; POLYMER; POLYSULFONE P 1700; SULFONE;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIABETIC NEPHROPATHY; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; RENOVASCULAR HYPERTENSION; URIC ACID BLOOD LEVEL; ARTIFICIAL MEMBRANE; BLOOD; CHRONIC KIDNEY FAILURE; METHODOLOGY; MIDDLE AGED; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; UREMIA;

ADULT; AGED; BICARBONATES; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; HYPOXANTHINE; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYMERS; REFERENCE VALUES; RENAL DIALYSIS; SULFONES; UREMIA; URIC ACID;

EID: 70349910575     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vanholder R, Argiles A, Baurmeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs. 2001;24:695-725.
2. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-43.
3. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73:1059-64.
4. Hsu CH, Patel SR, Young EW, Vanholder R. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol. 1991;260:F596-601.
5. Sampol J, Dussol B, Fenouillet E, et al. High adenosine and deoxyadenosine concentrations in mononuclear cells of hemodialyzed patients. J Am Soc Nephrol. 2001;12:1721-8.
6. Simmonds HA, Cameron JS, Morris GS, Fairbanks LD, Davies PM. Purine metabolites in uraemia. Adv Exp Med Biol. 1987;223:73-80.
7. Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem. 1992;38:1429-36.
8. Bullo B, Marlewski M, Smolenski RT, Rutkowski B, Swierczynski J, Manitius J. Erythrocyte nucleotides and blood hypoxanthine in patients with uremia evaluated immediately and 24 hours after hemodialysis. Ren Fail. 1996;18:247-52.
9. Bober J, Kedzierska K, Safranow K, et al. Influence of glucose in dialyzing fluid on purine concentrations in hemodialyzed patients with chronic renal failure. Nephron Clin Pract. 2003;95:c31-6.
10. Tekkanat KK, Port FK, Schmaltz S, Chen T, Fox IH. Excessive ATP degradation during hemodialysis against sodium acetate. J Lab Clin Med. 1988;112:686-93.
11. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73:1059-64.
12. Rutkowski B, Swierczynski J, Slominska E, et al. Disturbances of purine nucleotide metabolism in uremia. Semin Nephrol. 2004;24:479-83.
13. Smolenski RT, Skladanowski AC, Perko M, Zydowo MM. Adenylate degradation products release from the human myocardium during open heart surgery. Clin Chim Acta. 1989;182:63-73.
14. Arduini A, Mezzetti A, Porreca E, et al. Effect of ischemia and reperfusion on antioxidant enzymes and mitochondrial inner membrane proteins in perfused rat heart. Biochim Biophys Acta. 1988;970:113-21.
15. Kurokawa T, Kobayashi H, Nonami T, Harada A, Nakao A, Takagi H. Mitochondrial glutathione redox and energy producing function during liver ischemia and reperfusion. J Surg Res. 1996;66:1-5.
16. Woolliscroft JO, Fox IH. Increased body fluid purine levels during hypotensive events. Evidence for ATP degradation. Am J Med. 1986;81:472-8.
17. Shinzato T, Miwa M, Nakai S, et al. Role of adenosine in dialysis-induced hypotension. J Am Soc Nephrol. 1994;4:1987-94.
18. Imai E, Fujii M, Kohno Y, et al. Adenosine A1 receptor antagonist improves intradialytic hypotension. Kidney Int. 2006;69:877-83.
19. Bullo B, Marlewski M, Manitius J, Smolenski RT, Rutkowski B. [The levels of adenine nucleotides and hypoxanthine in blood of patients on long-term hemodialysis using dialysis fluid containing acetate or bicarbonate]. Przegl Lek. 1997;54:3-5. Polish.
20. Guieu R, Brunet P, Sampol J, et al. Adenosine and hemodialysis in humans. J Investig Med. 2001;49:56-67.
21. Smolenski RT, Lachno DR, Ledingham SJ, Yacoub MH. Determination of sixteen nucleotides, nucleosides and bases using high-performance liquid chromatography and its application to the study of purine metabolism in hearts for transplantation. J Chromatogr. 1990;527:414-20.
22. Yang BC, Khan S, Mehta JL. Blockade of plateletmediated relaxation in rat aortic rings exposed to xanthine-xanthine oxidase. Am J Physiol. 1994;266:H2212-9.
23. Berman RS, Martin W. Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol. 1993;108:920-6.
24. Linas SL, Whittenburg D, Repine JE. Role of xanthine oxidase in ischemia/reperfusion injury. Am J Physiol. 1990;258:F711-6.
25. Shahbazian H, Mombini H, Zand Moghaddam A, Jasemi M, Hosseini MA, Vaziri P. Changes in plasma concentrations of hypoxanthine and xanthine in renal vein as an index of delayed kidney allograft function. Urol J. 2006;3:225-9.
26. Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem. 1992;38:1429-36.
27. Langsdorf LJ, Zydney AL. Effect of uremia on the membrane transport characteristics of red blood cells. Blood. 1993;81:820-7.
28. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691-7.
29. Segura J, Campo C, Ruilope LM. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich). 2002;4:332-6.
30. Tseng CH. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int. 2005;68:796-801.
31. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron. 2001;87:333-9.
32. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-97.
33. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation. 2001;71:900-5.
34. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-9.
35. Ioachimescu AG, Brennan DM, Hoar BM, Kashyap SR, Hoogwerf BJ. Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study. Diabet Med. 2007;24:1369-74.